STAAR Surgical Files Proxy Materials
Ticker: STAA · Form: DEFA14A · Filed: Dec 10, 2025 · CIK: 718937
| Field | Detail |
|---|---|
| Company | Staar Surgical Co (STAA) |
| Form Type | DEFA14A |
| Filed Date | Dec 10, 2025 |
| Risk Level | low |
| Pages | 8 |
| Reading Time | 10 min |
| Key Dollar Amounts | $30.75, $2.75, $28, $18, $6,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, sec-filing, supplemental-materials
TL;DR
STAAR Surgical dropped more proxy docs, CEO sent out comms Dec 9th.
AI Summary
STAAR Surgical Company filed a Definitive Additional Materials (DEFA14A) on December 10, 2025. This filing indicates that on December 9, 2025, the Chief Executive Officer of STAAR Surgical Company distributed materials related to the company's proxy statement. The filing itself does not contain specific financial figures or detailed proposals but serves as supplementary information to the main proxy statement.
Why It Matters
This filing provides supplemental information to shareholders regarding company matters, which is crucial for informed voting on corporate governance and executive decisions.
Risk Assessment
Risk Level: low — The filing is a routine proxy statement supplement and does not contain information that inherently increases risk.
Key Players & Entities
- STAAR SURGICAL CO (company) — Registrant
- STAAR (company) — Abbreviation for STAAR Surgical Company
- 0001193125-25-313008 (filing_id) — Accession Number
- 1911 WALKER AVE (address) — Business and Mail Address
- MONROVIA (city) — Business and Mail City
- CA (state) — Business and Mail State
- 91016 (zip_code) — Business and Mail Zip Code
FAQ
What type of SEC filing is this?
This is a DEFA14A, specifically a Definitive Additional Materials filing.
When was this filing made?
The filing was made on December 10, 2025.
Who is the filer?
The filer is STAAR SURGICAL COMPANY.
What is the company's primary business?
The company is in the OPHTHALMIC GOODS industry, SIC code 3851.
When did the CEO send out related communications?
The Chief Executive Officer sent out communications on December 9, 2025.
Filing Stats: 2,540 words · 10 min read · ~8 pages · Grade level 13.4 · Accepted 2025-12-09 17:36:44
Key Financial Figures
- $30.75 — for each share of STAAR common stock to $30.75/share , an increase of $2.75/share from
- $2.75 — stock to $30.75/share , an increase of $2.75/share from the prior merger agreement.
- $28 — k on August 4, 2025 and ~10% premium to $28/share. Alcon's offer remains 100% cash.
- $18 — et exercised) with an exercise price of $18.75, you would be entitled to receive $6
- $6,000 — 18.75, you would be entitled to receive $6,000 ( i.e., 500 shares multiplied by the di
- $18.75 — multiplied by the difference of $30.75 -$18.75 =$12), less applicable tax withholding.
- $12 — ed by the difference of $30.75 -$18.75 =$12), less applicable tax withholding. Ou
Filing Documents
- d57431ddefa14a.htm (DEFA14A) — 36KB
- g57431g1210025455923.jpg (GRAPHIC) — 2KB
- g57431g1210025456111.jpg (GRAPHIC) — 2KB
- 0001193125-25-313008.txt ( ) — 42KB
Forward-Looking Statements
Forward-Looking Statements The information covered by this communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often contain words such as "anticipate," "believe," "expect," "plan," "estimate," "project," "continue," "will," "should," "may," and similar terms. All statements in this communication that are not statements of historical fact are forward-looking statements. These forward-looking statements are neither promises nor guarantees and involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from what is expressed or implied by the forward-looking statements, including, but not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the Alcon merger agreement or could cause the consummation of the proposed transaction to be delayed or to fail to occur; (2) the failure to obtain approval of the proposed transaction from the Company's stockholders; (3) the failure to obtain certain required regulatory approvals or the failure to satisfy any of the other closing conditions to the completion of the proposed transaction within the expected timeframes or at all; (4) risks related to disruption of management's attention from the Company's ongoing business operations due to the proposed transaction; (5) the effect of the announcement of the proposed transaction on the ability of the Company to retain and hire key personnel and maintain relationships with its customers, suppliers and others with whom it does business, or on its operating results and business generally; (6) the ability of the Company to meet expectations regarding the timing and completion of the transaction; (7) the outcome of any legal proceedings that may be instituted against the Company related to the proposed transaction; (8) the pos
Forward-looking statements speak only as of the date they are made and, except as may be required under
Forward-looking statements speak only as of the date they are made and, except as may be required under applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.